Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy

Reviews in Endocrine and Metabolic Disorders

Volumn 17, Issue 1, 2016, Pages 91-101

  Monnier, L ^a   Colette, C ^a   Dejager, S ^b   Owens, D R ^c  

^a UNIV MONTPELLIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Glucose homeostasis; Quality of diabetes therapy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BLOOD GLUCOSE MONITORING; CLINICAL FEATURE; DIET RESTRICTION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; RISK FACTOR; DIABETES MELLITUS; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS;

EID: 84955307981     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-016-9325-8     Document Type: Review

References (88)

1. Kirkman MS, Mc Carren M, Shah J, Duckworth W, Abraira C. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA cooperative study in diabetes. J Diabetes Complicat. 2006;20:75–80.
2. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–31.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
4. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
5. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, Mc Donald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care. 2002;25:750–86.
6. Sacks DB. Measurement of HbA1c. A new twist on the path to harmony. Diabetes Care. 2012;35:2674–80.
7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes and cardiovascular risk in non diabetic adults. N Engl J Med. 2010;362:800–11.
8. The Action to Control Cardiovasular Risk in Diabetes Study Group. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
9. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. For the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
11. Turnbull FM, Abraira C, Anderson RJ, Byinton RP, Chalmers JP, Duckworth WC et al, For the Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–2298.
12. Bejan-Angoulvant T, Cornu C, Archambault P, Tudrej B, Audier P, Brabant Y, et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes? Diabetes Metab. 2015;41:195–201.
13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149.
14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
15. Lachin JM, Orchard TJ, Nathan DM. For the DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43.
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-years follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
17. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.
18. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, et al. For the ACCORD study Group. Effects of intensive glycemic control on ischemic heart disease analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014;384:1936–41.
19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. New Engl J Med. 2008;358:580–91.
20. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. For the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015. doi:10.1056/NEJMoa 1504720.
21. American Diabetes Association. Standards of Medical Care in Diabetes-2016. 5. Glycemic targets. Diabetes Care 2016;39(Suppl 1):S39-S46.
22. IDF 2012 Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. http://dx.doi.org/10.1016/j.diabres.2012.10.001.
23. American Diabetes Association. Standards of Medical Care in Diabetes-2016. 2. Classification and diagnosis of diabetes. Diabetes Care 2016;39(Suppl 1):S13-S22.
24. Bolli GB, Gerich JE. The "dawn phenomenon" - a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984;310:746–50.
25. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005;11:55–64.
26. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes. Is this of concern? Diabetes Care. 2013;36:4057–62.
27. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care. 2007;30:263–9.
28. Monnier L, Lapinski H, Colette C. Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–5.
29. Monnier L, Colette C, Owens D. Post-prandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther. 2011;13(Suppl 1):S25–32.
30. Monnier L, Colette C, Dejager S, Owens DR. « Mild dysglycemia » in type 2 diabetes: to be neglected or not? J Diabetes Complicat. 2015;29:451–8.
31. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes. 1996;45:1044–50.
32. Porcelatti F, Lucidi P, Bolli GB, Fanelli CG. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care. 2013;36:3860–2.
33. De Feo P, Perriello G, Ventura MM, Calcinaro F, Basta G, Lolli C, et al. Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia. 1986;29:475–80.
34. Monnier L, Colette C, Dejager S, Owens D. Residual dysglycaemia when at target HbA1c of 7 % (53 mmol/mol) in persons with type 2 diabetes. Diabetes Res Clin Pract. 2014;104:371–5.
35. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycemic thresholds. Diabetologia. 2012;55:636–43.
36. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. The DIS group. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow up. Diabetologia. 1996;39:1577–83.
37. Temelkova-Kurkschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830–4.
38. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. For the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. Jama. 2003;290:486–94.
39. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.
40. The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463–76.
41. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens D. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with type 2 diabetes. Diabet Med. 2009;26:974–80.
42. Monnier L, Colette C. Glycemic variability. Should we and can we prevent it? Diabetes Care. 2008;31(Suppl 2):S150–4.
43. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? Diabetes Care. 2011;34:1058–9.
44. DeVries JH. Glucose variability: where is it important and how to measure it. Diabetes. 2013;62:1405–8.
45. Service FJ. Glucose variability. Diabetes. 2013;62:1398–404.
46. Rodbard D New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther. 2009;11:551–65.
47. Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther. 2009;11:623–33.
48. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetes. Acta Med Scand. 1965;177:95–102.
49. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther. 2006;8:165–73.
50. Suh S, Joung JY, Jin S-M, Kim MY, Bae JC, Park H-D, et al. Strong correlations between glycaemic variability and total glucose exposure in type 2 diabetes are limited to subjects with a satisfactory glycaemic control. Diabetes Metab. 2014;40:272–7.
51. Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, et al. Continuous glucose profiles with vildagliptin verus sitagliptin in add-on to metformin: results from the randomized optima study. Diabetes Metab. 2012;38:359–66.
52. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38:1610–4.
53. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38:1615–21.
54. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25:1439–43.
55. Brownlee M Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.
56. Brownlee M The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25.
57. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama. 2006;295:1681–7.
58. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–54.
59. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53:562–71.
60. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29:1486–90.
61. Lachin JM, Genuth S, Nathan DM, Zinman B. Rutledge BN for the DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes. 2008;57:995–1001.
62. Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting hyperglycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–6.
63. Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Insulin and atherosclerosis: how are they related? Diabetes Metab. 2013;39:111–7.
64. Hanefeld M Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab. 2014;40:391–9.
65. The FLAT-SUGAR Trial Investigators. Design of FLAT-SUGAR randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. Diabetes Care. 2015;38:1558–66.
66. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25:245–54.
67. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169–76.
68. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Biostat M. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.
69. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD Study. BMJ 2010;340:b4909.doi:10.1136/bmj.b4909.
70. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34(Suppl 2):S132–7.
71. Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014;63:2188–95.
72. Marques JLB, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997;14:648–54.
73. Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014;37:516–20.
74. Pistrosch F, Ganz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M. Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions. Acta Diabetol. 2015;52:889–95.
75. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC. A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus. The diabetes outcomes in veterans study (DOVES). Arch Intern Med. 2004;164:1445–50.
76. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycemia in type 1 diabetes. Diabetologia. 2007;50:2553–61.
77. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13:813–8.
78. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7:139–53.
79. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.
80. Scheen A, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179–90.
81. Ahrén B, Lequizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal M). Diabetes Care. 2013;36:2543–50.
82. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Duration-2 study group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431–9.
83. Bolli GB, Owens DR. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes. Diabetes Obes Metab. 2014;15:588–601.
84. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. For the saxagliptin 014 study group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–55.
85. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.
86. Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab. 2013;39:485–96.
87. Holman RR, Farmer AJ. Davies, levy JC, darbyshire JL, Keenan JF et al, 4-T study group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
88. Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al. For the 4B study group. Glucagon-like peptide receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37:2763–73.